Affiliations: [a] Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
| [b] Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA
| [c] Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| [d] School of Behavioral and Brain Sciences, University of Texas at Dallas, Dallas, TX, USA
Correspondence:
[*]
Correspondence to: Christian LoBue, PhD, 5323 Harry Hines Blvd, Dallas, TX 75390, USA. Tel.: +1 214 648
4646; Fax: +1 214 648 4660; E-mail: [email protected].
Abstract: Multiple pharmacologic agents now have been approved in the United States and other countries as treatment to slow disease and clinical progression for Alzheimer’s disease. Given these treatments have not been proven to lessen the cognitive deficits already manifested in the Alzheimer’s Clinical Syndrome (ACS), and none are aimed for another debilitating dementia syndrome identified as primary progressive aphasia (PPA), there is an urgent need for new, safe, tolerable, and efficacious treatments to mitigate the cognitive deficits experienced in ACS and PPA. Noninvasive brain stimulation has shown promise for enhancing cognitive functioning, and there has been interest in its potential therapeutic value in ACS and PPA. This review critically examines the evidence of five technologies in ACS and PPA: transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), transcranial random noise stimulation (tRNS), repetitive transcranial magnetic stimulation (rTMS), and noninvasive vagus nerve stimulation (nVNS). Many randomized controlled trials of tDCS and rTMS report positive treatment effects on cognition in ACS and PPA that persist out to at least 8 weeks, whereas there are few trials for tACS and none for tRNS and nVNS. However, most positive trials did not identify clinically meaningful changes, underscoring that clinical efficacy has yet to be established in ACS and PPA. Much is still to be learned about noninvasive brain stimulation in ACS and PPA, and shifting the focus to prioritize clinical significance in addition to statistical significance in trials could yield greater success in understanding its potential cognitive effects and optimal parameters.
